CYDY submitted multiply application to FDA for BTD for the treatment on mTNBC

January 30 , 2020 application , this application was based on 2 patients .
The first patient was from our phase 1b/2 trial for mTNBC.
The second patient was from eIND treatment for HER2+ metastatic , stage 4 breast cancer , I believe this was M-i-L

Then November 8 , 2021 application was submitted for another BTD in treatment of mTNBC.
This submission was based on analysis of data from a pooled population of our 28 patients with mTNBC.

Those were the patients ,
--10 from phase 1b/2 in mTNBC
--2 from basket trial.
--16 from compassionate use ..

I believe now in 2025 with our 5 patients from the 28 surviving that long.
We will have a very good chance for BTD ,
Just need to apply..